October | 2006 | GlobeImmune

GlobeImmune Announces Presentation of Positive Interim Results from a Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection

October 30, 2006

LOUISVILLE, CO, October 30, 2006, GlobeImmune, Inc. today announced positive interim results from Study GI-5005-01, a randomized, placebo-controlled, multi-center, dose-escalation, Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus (HCV). The data were presented today at … Continue reading →

GlobeImmune Announces GI-5005 Tarmogen Data for Chronic Hepatitis C Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD)

October 17, 2006

LOUISVILLE, CO, October 17, 2006, GlobeImmune, Inc., announced today that the interim results from a placebo-controlled Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus will be presented at the 57th Annual Meeting of the American … Continue reading →